Q-omics provides the consensus-scored TMEM213 profile across patient tissues and cancer cell-line models. TMEM213 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TMEM213 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, TMEM213 RNA expression shows 11,529 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRC, and GBM as cancer lineages where TMEM213 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM213 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM213 survival associations across molecular data types. TMEM213 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM213 RNA expression–survival associations across cancer types. High TMEM213 expression shows unfavorable associations in ACC, LIHC and COAD, but favorable associations in KIRC, LUAD and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TMEM213 RNA expression.
This table summarizes TMEM213 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM213. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM213 shows lower tumor expression in KIRC, KIRP, HNSC, LUSC and BRCA and higher tumor expression in UCEC. The KIRC box plot shows higher TMEM213 RNA expression in normal versus tumor tissue (log2 FC = −7.064, t-test p < 0.001).
This table shows molecular features associated with TMEM213 in patient tissues and cancer cell lines. In patient samples, TMEM213 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM213 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
